查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1791666

全球內視鏡逆行性造影市場

Endoscopic Retrograde Cholangiopancreatography
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年，全球內視鏡逆行性造影市場規模將達 75 億美元

全球內視鏡逆行性造影市場規模預計在2024年達到47億美元，預計在2024-2030年的分析期間內將以8.3%的複合年成長率成長，到2030年將達到75億美元。內視鏡檢查是本報告分析的細分市場之一，預計其複合年成長率將達到9.6%，到分析期末將達到29億美元。內視鏡治療設備細分市場在分析期間的複合年成長率預計為8.7%。

美國市場預計將達到 12 億美元，中國市場複合年成長率將達到 8.0%

美國視鏡逆行性胰造影市場規模預計2024年達到12億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到12億美元，在2024-2030年的分析期間內，複合年成長率為8.0%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為7.8%和6.9%。在歐洲，預計德國市場的複合年成長率約為6.5%。

全球內視鏡逆行性造影(ERCP) 市場 - 主要趨勢與促進因素摘要

為什麼 ERCP 是胃腸病學和肝膽胰疾病中的一個重要程序？

內視鏡逆行性胰造影(ERCP) 是一種微創內視鏡技術，用於診斷和治療膽道及胰臟疾病，包括膽結石、膽管狹窄、胰臟腫瘤和慢性胰臟炎。此技術結合內視鏡和螢光透視技術，可觀察並治療膽道和胰管疾病，從而減少開放性手術的需求。

膽囊疾病、胰臟癌和膽管阻塞的發生率不斷上升，加上老化人口更容易罹患肝膽疾病，這些因素顯著增加了對內視鏡逆行性胰膽管攝影 (ERCP) 的需求。此外，ERCP 配件（例如自膨式金屬支架 (SEMS)、括約肌切開器和球囊擴張器）的進步，正在提高手術成功率和患者預後。隨著醫院和專科胃腸病中心內視鏡檢查能力的提升，ERCP 的應用預計將進一步成長。

ERCP 技術有哪些最新創新？

內視鏡逆行性胰膽管攝影 (ERCP) 的最新進展著重於增強視覺化效果、減少併發症並提高治療精準度。高清數位透視和人工智慧輔助造影造影解讀技術的進步，提高了對小病變和膽管異常的檢測率。我們先進的膽管鏡平台 SpyGlass 直接可視化系統能夠即時成像膽管和胰管，從而實現有針對性的切片檢查採集和精準引導取石。

生物分解性膽道支架的引入減少了再次手術的需求，提高了患者的便利性，並降低了醫療成本。此外，機器人輔助內視鏡逆行性胰膽管攝影 (ERCP) 技術正在研究中，以提高手術準確性，減少操作人員疲勞，並改善複雜膽道和胰臟疾病的治療效果。隨著 ERCP 技術的不斷發展，基於機器學習的預測分析與人工智慧引導的內視鏡導航的整合有望提高該手術的準確性和安全性。

推動 ERCP 市場成長的因素有哪些？

內視鏡逆行性胰膽管攝影 (ERCP) 市場的成長動力源自於胃腸道疾病發病率的上升、微創技術的日益普及以及內視鏡成像和介入工具的進步。膽道和胰臟疾病患者對非手術治療的日益偏好，加上先進內視鏡中心的擴張，共同推動了市場需求。此外，胰臟癌發生率的上升以及對治療性內視鏡手術需求的不斷成長，也促進了 ERCP 的普及。

下一代 ERCP 設備、人工智慧膽道鏡平台以及機器人輔助內視鏡整合的監管批准預計將進一步加速市場成長。持續的技術進步、不斷增加的醫療保健投資以及全球專科胃腸病學護理服務的普及，預計將推動 ERCP 市場在未來幾年大幅擴張。

部分

產品（內視鏡、內視鏡治療設備、視覺化系統、能量設備等）；程序（膽道括約肌切開術、膽道支架置入術、膽道擴張術、胰臟括約肌切開術、胰管支架置入術、胰管擴張術）；最終用戶（醫院、門診病人設施）

受訪公司範例

  • Ambu A/S
  • Ambu Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Bio-Rad Medisys Pvt. Ltd.
  • Boston Scientific Corporation
  • CONMED Corporation
  • Cook Medical
  • DCC Healthcare（Medi-Globe GmbH）
  • Fujifilm Holdings Corporation
  • HOBBS MEDICAL
  • HOYA Corporation
  • Huger Medical Instrument Co., Ltd
  • Johnson & Johnson
  • KARL STORZ SE & Co. KG
  • Lancetinc Medical
  • LeoMed
  • Medtronic PLC
  • Merit Medical Systems
  • Olympus Corporation

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global 特定產業產業SLM 的典型規範，而是建立了一個從世界各地專家收集的內容庫，包括影片錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP30780

Global Endoscopic Retrograde Cholangiopancreatography Market to Reach US$7.5 Billion by 2030

The global market for Endoscopic Retrograde Cholangiopancreatography estimated at US$4.7 Billion in the year 2024, is expected to reach US$7.5 Billion by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Endoscopes, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Endotherapy Devices segment is estimated at 8.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 8.0% CAGR

The Endoscopic Retrograde Cholangiopancreatography market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.8% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Market - Key Trends & Drivers Summarized

Why Is ERCP a Critical Procedure in Gastrointestinal and Hepatobiliary Medicine?

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a minimally invasive endoscopic technique used for the diagnosis and treatment of biliary and pancreatic disorders, including gallstones, bile duct strictures, pancreatic tumors, and chronic pancreatitis. This procedure combines endoscopy and fluoroscopy to visualize and treat conditions affecting the biliary and pancreatic ducts, reducing the need for open surgical interventions.

The rising prevalence of gallbladder disease, pancreatic cancer, and bile duct obstructions, along with increasing geriatric populations prone to hepatobiliary disorders, has significantly increased the demand for ERCP procedures. Additionally, advancements in ERCP accessories, including self-expanding metal stents (SEMS), sphincterotomes, and balloon dilators, have improved procedural success rates and patient outcomes. As hospitals and specialty gastroenterology centers expand their endoscopic capabilities, ERCP adoption is expected to grow further.

What Are the Latest Innovations in ERCP Technology?

Recent advancements in ERCP have focused on enhancing visualization, reducing complications, and improving therapeutic precision. The development of high-definition digital fluoroscopy and AI-assisted cholangiography interpretation has improved the detection of small lesions and bile duct abnormalities. SpyGlass Direct Visualization Systems, a state-of-the-art cholangioscopy platform, allows real-time imaging of bile and pancreatic ducts, enabling targeted biopsy collection and precision-guided stone removal.

The introduction of biodegradable biliary stents has reduced the need for repeat procedures, improving patient convenience and lowering healthcare costs. Additionally, robot-assisted ERCP techniques are being explored to enhance procedural precision, reduce operator fatigue, and improve outcomes in complex biliary and pancreatic disorders. As ERCP continues to evolve, the integration of machine learning-based predictive analytics and AI-guided endoscopic navigation is expected to enhance procedural accuracy and safety.

What Is Driving the Growth of the ERCP Market?

The growth in the ERCP market is driven by rising gastrointestinal disorders, increased adoption of minimally invasive techniques, and advancements in endoscopic imaging and intervention tools. The growing preference for non-surgical treatments for biliary and pancreatic diseases, combined with the expansion of advanced endoscopy centers, has fueled market demand. Additionally, the rise in pancreatic cancer incidence and the increasing need for therapeutic endoscopic procedures have contributed to ERCP adoption.

Regulatory approvals for next-generation ERCP devices, AI-powered cholangioscopy platforms, and the integration of robotic-assisted endoscopy are expected to further accelerate market growth. With continued technological advancements, rising healthcare investments, and increasing global access to specialized gastroenterology care, the ERCP market is poised for substantial expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Endoscopic Retrograde Cholangiopancreatography market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices, Others); Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, Pancreatic Duct Dilation); End-Use (Hospitals, Outpatient Facilities)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • Ambu A/S
  • Ambu Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Bio-Rad Medisys Pvt. Ltd.
  • Boston Scientific Corporation
  • CONMED Corporation
  • Cook Medical
  • DCC Healthcare (Medi-Globe GmbH)
  • Fujifilm Holdings Corporation
  • HOBBS MEDICAL
  • HOYA Corporation
  • Huger Medical Instrument Co., Ltd
  • Johnson & Johnson
  • KARL STORZ SE & Co. KG
  • Lancetinc Medical
  • LeoMed
  • Medtronic PLC
  • Merit Medical Systems
  • Olympus Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Endoscopic Retrograde Cholangiopancreatography - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Pancreatic and Biliary Disorders Drives Demand for ERCP Procedures Globally
    • Advancements in ERCP Devices Enhance Procedural Accuracy and Reduce Complication Rates
    • Aging Population and Gallstone-Related Complications Fuel Volume Growth in ERCP Interventions
    • Integration of Fluoroscopy and Digital Imaging Tools Supports Complex ERCP Navigation and Diagnosis
    • Availability of Disposable Duodenoscopes Addresses Contamination Risks and Improves Infection Control
    • Increase in Minimally Invasive Biliary Drainage Techniques Expands Use of ERCP in Non-Surgical Settings
    • Specialty Training Programs and GI Fellowship Expansion Promote Adoption of Advanced ERCP Procedures
    • Growth in Therapeutic ERCP for Stent Placement and Stone Extraction Strengthens Hospital Utilization
    • Hybrid Endoscopic Procedures Combine ERCP With EUS for Improved Visualization and Targeting
    • Coding and Reimbursement Updates Enhance Procedural Profitability for Outpatient ERCP Settings
    • Development of Smart Guidewires and Cannulation Devices Increases Success Rate in Complex ERCP
    • Global Expansion of Endoscopy Suites and Digestive Health Centers Fuels ERCP Procedure Adoption
    • Portable Imaging and AI-Guided ERCP Platforms Enable Better Access in Community and Rural Hospitals
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Endoscopic Retrograde Cholangiopancreatography Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Endoscopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Endoscopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Endotherapy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Endotherapy Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Visualization Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Visualization Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Energy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Energy Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pancreatic Duct Stenting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Pancreatic Duct Stenting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pancreatic Duct Dilation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Pancreatic Duct Dilation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Biliary Sphincterotomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Biliary Sphincterotomy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Biliary Stenting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Biliary Stenting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Biliary Dilatation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Biliary Dilatation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Pancreatic Sphincterotomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Pancreatic Sphincterotomy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Outpatient Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Outpatient Facilities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 30: USA Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • CANADA
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • JAPAN
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • CHINA
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 48: China Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • EUROPE
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • FRANCE
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 66: France Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: France 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • GERMANY
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 72: Germany Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Germany 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 78: Italy Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Italy 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • UNITED KINGDOM
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 84: UK Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: UK 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Asia-Pacific 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 102: Rest of World Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of World 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030

IV. COMPETITION